Patents by Inventor Glenn Noronha

Glenn Noronha has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20110212077
    Abstract: The invention provides biaryl meta-pyrimidine compounds having the general structure (A). The pyrimidine compounds of the invention are capable of inhibiting kinases, such as members of the Jak kinase family, and various other specific receptor and non-receptor kinases.
    Type: Application
    Filed: August 24, 2010
    Publication date: September 1, 2011
    Applicant: TargeGen, Inc.
    Inventors: Glenn Noronha, Chi Ching Mak, Jianguo Cao, Joel Renick, Andrew McPherson, Binqi Zeng, Ved P. Pathak, Daniel L. Lohse, John D. Hood, Richard M. Soll
  • Publication number: 20100330030
    Abstract: Compositions and methods and are provided for treating disorders associated with compromised vasculostasis. Invention methods and compositions are useful for treating a variety of disorders including for example, stroke, myocardial infarction, cancer, ischemia/reperfusion injury, autoimmune diseases such as rheumatoid arthritis, eye diseases such as retinopathies or macular degeneration or other vitreoretinal diseases, inflammatory diseases, vascular leakage syndrome, edema, transplant rejection, adult/acute respiratory distress syndrome (ARDS), and the like.
    Type: Application
    Filed: May 14, 2010
    Publication date: December 30, 2010
    Applicant: TargeGen, Inc.
    Inventors: Wolfgang Wrasidlo, John Doukas, Ivor Royston, Glenn Noronha, John D. Hood, Elena Dneprovskaia, Xianchang Gong, Ute Splittgerber, Ningning Zhao
  • Publication number: 20100278811
    Abstract: Compositions and methods and are provided for treating disorders associated with compromised vasculostasis. Invention methods and compositions are useful for treating a variety of disorders including for example, stroke, myocardial infarction, cancer, ischemia/reperfusion injury, autoimmune diseases such as rheumatoid arthritis, eye diseases such as retinopathies or macular degeneration or other vitreoretinal diseases, inflammatory diseases, vascular leakage syndrome, edema, transplant rejection, adult/acute respiratory distress syndrome (ARDS), and the like.
    Type: Application
    Filed: December 1, 2009
    Publication date: November 4, 2010
    Inventors: Wolfgang Wrasidlo, John Doukas, Ivor Royston, Glenn Noronha, John D. Hood, Elena Dneprovskaia, Xianchang Gong, Ute Splittgerber, Ningning Zhao
  • Patent number: 7825246
    Abstract: The invention provides biaryl meta-pyrimidine compounds having the general structure (A). The pyrimidine compounds of the invention are capable of inhibiting kinases, such as members of the Jak kinase family, and various other specific receptor and non-receptor kinases.
    Type: Grant
    Filed: April 26, 2007
    Date of Patent: November 2, 2010
    Assignee: TargeGen, Inc.
    Inventors: Glenn Noronha, Chi Ching Mak, Jianguo Cao, Joel Renick, Andrew McPherson, Binqi Zeng, Ved P. Pathak, Daniel L. Lohse, John D. Hood, Richard M. Soll
  • Patent number: 7691858
    Abstract: Compositions and methods and are provided for treating disorders associated with compromised vasculostasis. Invention methods and compositions are useful for treating a variety of disorders including for example, stroke, myocardial infarction, cancer, ischemia/reperfusion injury, autoimmune diseases such as rheumatoid arthritis, eye diseases such as uveitis, retinopathies or macular degeneration, macular edema or other vitreoretinal diseases, inflammatory diseases such as autoimmune diseases, vascular leakage syndrome, edema, or diseases involving leukocyte activation, transplant rejection, respiratory diseases such as asthma, adult or acute respiratory distress syndrome (ARDS), chronic obstructive pulmonary disease, and the like.
    Type: Grant
    Filed: April 25, 2007
    Date of Patent: April 6, 2010
    Assignee: TargeGen, Inc.
    Inventors: John Doukas, Chi Ching Mak, Elena Dneprovskaia, Glenn Noronha
  • Publication number: 20090286789
    Abstract: The invention provides methods of treating a disease selected from systemic sclerosis, rheumatoid arthritis, mastocytosis, and chronic eosinophilic leukemia comprising administering biaryl meta-pyrimidine compounds having the general structure (A) to a subject in need thereof. The pyrimidine compounds of the invention are capable of inhibiting kinases, such as members of the JAK kinase family, and various other specific receptor and non-receptor kinases.
    Type: Application
    Filed: October 14, 2008
    Publication date: November 19, 2009
    Applicant: Targegen, Inc.
    Inventors: John D. Hood, Glenn Noronha
  • Publication number: 20090275582
    Abstract: The invention provides biaryl meta-pyrimidine compounds having the general structure (A). The pyrimidine compounds of the invention are capable of inhibiting kinases, such as members of the Jak kinase family, and various other specific receptor and non-receptor kinases.
    Type: Application
    Filed: October 17, 2008
    Publication date: November 5, 2009
    Inventors: Glenn Noronha, John D. Hood, Richard M. Soll
  • Publication number: 20090275569
    Abstract: The invention provides benzotriazine compounds having formula (I). The benzotriazine compounds of the invention are capable of inhibiting kinases, such members of the Src kinase family, and various other specific receptor and non-receptor kinases.
    Type: Application
    Filed: September 9, 2008
    Publication date: November 5, 2009
    Inventors: Xianchang Gong, Kathy Barrett, Jianguo Cao, Colleen Gritzen, Glenn Noronha, John D. Hood, Chi Ching Mak, Andrew McPherson, Ved Prakash Pathak, Joel Renick, Richard M. Soll, Ute Splittgerber, Wolfgang Wrasidlo, Ningning Zhao, Elena Dneprovskaia, Binqi Zeng, Glenn Noronha
  • Patent number: 7528143
    Abstract: The invention provides biaryl meta-pyrimidine compounds having the general structure (A). The pyrimidine compounds of the invention are capable of inhibiting kinases, such as members of the Jak kinase family, and various other specific receptor and non-receptor kinases.
    Type: Grant
    Filed: October 26, 2006
    Date of Patent: May 5, 2009
    Assignee: TargeGen, Inc.
    Inventors: Glenn Noronha, Chi Ching Mak, Jianguo Cao, Joel Renick, Andrew McPherson, Binqi Zeng, Ved P. Pathak, Daniel L. Lohse, John D. Hood, Richard M. Soll
  • Patent number: 7456176
    Abstract: The invention provides benzotriazine compounds having formula (I). The benzotriazine compounds of the invention are capable of inhibiting kinases, such members of the Src kinase family, and various other specific receptor and non-receptor kinases.
    Type: Grant
    Filed: April 7, 2005
    Date of Patent: November 25, 2008
    Assignee: TargeGen, Inc.
    Inventors: Glenn Noronha, Kathy Barrett, Jianguo Cao, Colleen Gritzen, Xianchang Gong, John D. Hood, Chi Ching Mak, Andrew McPherson, Ved Prakash Pathak, Joel Renick, Richard M. Soll, Ute Splittgerber, Wolfgang Wrasidlo, Binqi Zeng, Ningning Zhao, Elena Dneprovskaia
  • Publication number: 20080027070
    Abstract: Compounds having the general structure (A) are provided. The compounds of the invention are capable of inhibiting kinases, such as members of the Src kinase family, Vegfr and various other specific receptor and non-receptor kinases.
    Type: Application
    Filed: July 2, 2007
    Publication date: January 31, 2008
    Applicant: TargeGen, Inc.
    Inventors: Glenn Noronha, Jianguo Cao, Colleen Gritzen, Chi Ching Mak, Andrew McPherson, Ved Pathak, Joel Renick, Richard Soll, Binqi Zeng, Elena Dneprovskaia
  • Publication number: 20070259904
    Abstract: The invention provides biaryl meta-pyrimidine compounds having the general structure (A). The pyrimidine compounds of the invention are capable of inhibiting kinases, such as members of the Jak kinase family, and various other specific receptor and non-receptor kinases.
    Type: Application
    Filed: April 26, 2007
    Publication date: November 8, 2007
    Applicant: TargeGen, Inc.
    Inventors: Glenn Noronha, Chi Mak, Jianguo Cao, Joel Renick, Andrew McPherson, Binqi Zeng, Ved Pathak, Daniel Lohse, John Hood, Richard Soll
  • Publication number: 20070259876
    Abstract: Compositions and methods and are provided for treating disorders associated with compromised vasculostasis. Invention methods and compositions are useful for treating a variety of disorders including for example, stroke, myocardial infarction, cancer, ischemia/reperfusion injury, autoimmune diseases such as rheumatoid arthritis, eye diseases such as uveitis, retinopathies or macular degeneration, macular edema or other vitreoretinal diseases, inflammatory diseases such as autoimmune diseases, vascular leakage syndrome, edema, or diseases involving leukocyte activation, transplant rejection, respiratory diseases such as asthma, adult or acute respiratory distress syndrome (ARDS), chronic obstructive pulmonary disease, and the like.
    Type: Application
    Filed: April 25, 2007
    Publication date: November 8, 2007
    Applicant: TargeGen, Inc.
    Inventors: John Doukas, Chi Mak, Elena Dneprovskaia, Glenn Noronha
  • Publication number: 20070208019
    Abstract: Compositions and methods and are provided for treating disorders associated with compromised vasculostasis. Invention methods and compositions are useful for treating a variety of disorders including for example, stroke, myocardial infarction, cancer, ischemia/reperfusion injury, autoimmune diseases such as rheumatoid arthritis, eye diseases such as retinopathies or macular degeneration or other vitreoretinal diseases, inflammatory diseases, vascular leakage syndrome, edema, transplant rejection, adult/acute respiratory distress syndrome (ARDS), and the like.
    Type: Application
    Filed: January 11, 2007
    Publication date: September 6, 2007
    Inventors: Wolfgang Wrasidlo, John Doukas, Ivor Royston, Glenn Noronha, John Hood, Elena Dneprovskaia, Xianchang Gong, Ute Splittgerber, Ningning Zhao
  • Publication number: 20070191405
    Abstract: The invention provides biaryl meta-pyrimidine compounds having the general structure (A). The pyrimidine compounds of the invention are capable of inhibiting kinases, such as members of the Jak kinase family, and various other specific receptor and non-receptor kinases.
    Type: Application
    Filed: October 26, 2006
    Publication date: August 16, 2007
    Applicant: TargeGen, Inc.
    Inventors: Glenn Noronha, Chi Mak, Jianguo Cao, Joel Renick, Andrew McPherson, Binqi Zeng, Ved Pathak, Daniel Lohse, John Hood, Richard Soll
  • Publication number: 20070161645
    Abstract: A compound is provided, having the general structure (A): wherein A is an aryl or heteroaryl group, Y is a hydrophbic linking moiety, and L is a substitutent. The compound (A) can be used for treatment of various angiogenic-associated or hematologic disorders, such as myeloproliferative disorders in patients who do not respond to kinase-inhibition therapy that comprises administering currently used medications.
    Type: Application
    Filed: October 31, 2006
    Publication date: July 12, 2007
    Applicant: TargeGen, Inc.
    Inventors: Glenn Noronha, Jianguo Cao, Binqi Zeng, Chi Mak, Andrew McPherson, Joel Renick, Ved Pathak, Chun Chow, Moorthy Palanki, Richard Soll, Daniel Lohse, John Hood, Elena Dneprovskaia
  • Publication number: 20070149508
    Abstract: A compound is provided, having the general structure (A): wherein A is an (un)substituted aryl or (un)substituted heteroaryl moiety, G is N, CH, or CR, R is an unsubstituted or substituted lower alkyl, Y is a hydrophobic linking moiety, and L is a substitutent as defined. The compound (A) can be used for treatment of various angiogenic and hematological-associated disorders, such as myeloproliferative disorder in patients who do not respond to kinase-inhibition therapy that comprises administering approved medications.
    Type: Application
    Filed: October 31, 2006
    Publication date: June 28, 2007
    Applicant: TargeGen, Inc.
    Inventors: Glenn Noronha, Jianguo Cao, Binqi Zeng, Chi Mak, Andrew McPherson, Joel Renick, Ved Pathak, Chun Chow, Moorthy Palanki, Richard Soll, Daniel Lohse, John Hood, Elena Dneprovskaia
  • Patent number: 7208493
    Abstract: Compositions and methods and are provided for treating disorders associated with compromised vasculostasis. Invention methods and compositions are useful for treating a variety of disorders including for example, stroke, myocardial infarction, cancer, ischemia/reperfusion injury, autoimmune diseases such as rheumatoid arthritis, eye diseases such as retinopathies or macular degeneration or other vitreoretinal diseases , inflammatory diseases, vascular leakage syndrome, edema, transplant rejection, adult/acute respiratory distress syndrome (ARDS), and the like.
    Type: Grant
    Filed: October 2, 2003
    Date of Patent: April 24, 2007
    Assignee: TargeGen, Inc.
    Inventors: Wolfgang Wrasidlo, John Doukas, Ivor Royston, Glenn Noronha, John D. Hood, Elena Dneprovskaia, Xianchang Gong, Ute Splittgerber, Ningning Zhao
  • Publication number: 20060247250
    Abstract: The invention provides pyrimidine compounds having formula A. The pyrimidine compounds of the invention are capable of inhibiting kinases, such as members of the Src kinase family, and various other specific receptor and non-receptor kinases.
    Type: Application
    Filed: March 15, 2006
    Publication date: November 2, 2006
    Applicant: TargeGen, Inc.
    Inventors: Jianguo Cao, Richard Soll, Glenn Noronha, Kathy Barrett, Colleen Gritzen, John Hood, Chi Mak, Andrew McPherson, Ved Pathak, Joel Renick, Ute Splittgerber, Binqi Zeng
  • Patent number: 7045361
    Abstract: Fluorescent biosensor molecules, fluorescent biosensors and systems, as well as methods of making and using these biosensor molecules and systems are described. These biosensor molecules address the problem of obtaining fluorescence emission at wavelengths greater than about 500 nm. Biosensor molecules generally include an (1) an acridine-based fluorophore, (2) a linker moiety and (3) a boronate substrate recognition/binding moiety, which binds polyhydroxylate analytes, such as glucose. These biosensor molecules further include a “switch” element that is drawn from the electronic interactions among these submolecular components. This fluorescent switch is generally “off” in the absence of bound polyhydroxylate analyte and is generally “on” in the presence of bound polyhydroxylate analyte. Thus, the reversible binding of a polyhydroxylate analyte essentially turns the fluorescent switch “on” and “off”.
    Type: Grant
    Filed: September 12, 2001
    Date of Patent: May 16, 2006
    Assignee: Medtronic MiniMed, Inc.
    Inventors: Aaron M. Heiss, Joseph C. Walsh, David J. Vachon, Glenn Noronha, Jonathan Reilly, Bill C. Ponder, William P. Van Antwerp